Wikisage, the free encyclopedia of the second generation and digital heritage, wishes you merry holidays and a happy new year!
Sildenafil: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
The «blue pill» was marketed by Pfizer as [[Eretiledisfunction|DE]] | The «blue pill» was marketed by Pfizer as an agent to treat [[Eretiledisfunction|DE]] and recently studies as preventive of premature ejaculation | ||
<ref>Krishnappa P, Fernandez-Pascual E, Carballido J, Martinez-Salamanca JI. Sildenafil/Viagra in the treatment of premature ejaculation. Int J Impot Res. 2019 Mar;31(2):65-70. doi: 10.1038/s41443-018-0099-2. Epub 2019 Mar 5. PMID: 30837718.</ref> | <ref>Krishnappa P, Fernandez-Pascual E, Carballido J, Martinez-Salamanca JI. Sildenafil/Viagra in the treatment of premature ejaculation. Int J Impot Res. 2019 Mar;31(2):65-70. doi: 10.1038/s41443-018-0099-2. Epub 2019 Mar 5. PMID: 30837718.</ref> | ||
Graciano et al (2017) present a mechanism for hepatotoxicity of this medicine, also many counterfeit plant preparations, involving CYP3A4 enzymes <ref>https://www.europeanreview.org/wp/wp-content/uploads/17-22-Sildenafil-associated-hepatoxicity-a-review-of-the-literature.pdf</ref> | Graciano et al (2017) present a mechanism for hepatotoxicity of this medicine, also many counterfeit plant preparations, involving CYP3A4 enzymes <ref>https://www.europeanreview.org/wp/wp-content/uploads/17-22-Sildenafil-associated-hepatoxicity-a-review-of-the-literature.pdf</ref> | ||
| Line 5: | Line 5: | ||
Phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, were approved for treatment of pulmonary arterial hypertension (PAH) by the Food and Drug Administration (FDA) in 2005, which holds promise in improving quality of life and therefore making this class of medications effective palliative therapy agents<ref>Bhogal S, Khraisha O, Al Madani M, Treece J, Baumrucker SJ, Paul TK. Sildenafil for Pulmonary Arterial Hypertension. Am J Ther. 2019 Jul/Aug;26(4): e520-e526. doi: 10.1097/MJT.0000000000000766. PMID: 30946047</ref> | Phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, were approved for treatment of pulmonary arterial hypertension (PAH) by the Food and Drug Administration (FDA) in 2005, which holds promise in improving quality of life and therefore making this class of medications effective palliative therapy agents<ref>Bhogal S, Khraisha O, Al Madani M, Treece J, Baumrucker SJ, Paul TK. Sildenafil for Pulmonary Arterial Hypertension. Am J Ther. 2019 Jul/Aug;26(4): e520-e526. doi: 10.1097/MJT.0000000000000766. PMID: 30946047</ref> | ||
==ATC== | ==ATC== | ||
Urological agents | |||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | {| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | ||
|colspan=2| <center> | |colspan=2| <center> | ||
[[File:Pilule_bleu17_28_29.jpg|:Pilule_bleu17_28_29.jpg|92px]] | [[File:Pilule_bleu17_28_29.jpg|:Pilule_bleu17_28_29.jpg|92px]] | ||
: [[wikipedia:sildenafil|sildenafil]] | : [[wikipedia:sildenafil|sildenafil]] | ||
<ref> | <ref>https://www.whocc.no/atc_ddd_index/?code=G04BE03</ref></center> | ||
|} | |} | ||
==Links== | ==Links== | ||
Latest revision as of 15:58, 17 January 2021
The «blue pill» was marketed by Pfizer as an agent to treat DE and recently studies as preventive of premature ejaculation [1] Graciano et al (2017) present a mechanism for hepatotoxicity of this medicine, also many counterfeit plant preparations, involving CYP3A4 enzymes [2] Further questions remains[3] Phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, were approved for treatment of pulmonary arterial hypertension (PAH) by the Food and Drug Administration (FDA) in 2005, which holds promise in improving quality of life and therefore making this class of medications effective palliative therapy agents[4]
ATC
Urological agents
|
Links
comparable efficacy shows tadalafil [6][7]
- Preeclampsia
a recent study excluded tadalafil [8]
PH
Treatment with oral sildenafil 40 mg t.i.d. for 6 months in patients with persistent PH after successful correction of VHD is associated to unfavourable clinical outcomes as compared to placebo[9]
Bosentan
McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25. PMID: 26113687.
Immune system
..can affect innate and adaptative immune systems
Source
References
| References: |
|